You can buy Tucadx at the lowest price at Nextgen.ooo online pharmacy. Tucatinib is used with trastuzumab and capecitabine in the treatment of unresectable or metastatic HER2-positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer who have not responded adequately to other chemotherapy regimens.
 
Tucatinib is indicated in combination with trastuzumab and capecitabine for the treatment of adults diagnosed with advanced unresectable or metastatic HER2-positive breast cancer. It is also indicated in combination with trastuzumab for the treatment of adult patients with HER2-positive RAS wild-type unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. This indication is approved under accelerated approval; as such, it is contingent on validation and description of clinical benefit in confirmatory studies.